Hematology Frontier

From December 6–9, 2025, the 67th American Society of Hematology (ASH) Annual Meeting was held in Orlando, bringing together the latest global advances in hematologic research and clinical practice. Multiple…

From December 6–9, 2025, the 67th American Society of Hematology (ASH) Annual Meeting was held in Orlando. As the world’s most influential and comprehensive academic event in hematology, ASH annually gathers tens of thousands of experts to present breakthroughs spanning basic research to clinical innovation. This year, the team led by Professor Jia Wei of Tongji Hospital, Huazhong University of Science and Technology, had seven studies accepted—one oral presentation and six posters—covering CAR-T therapy, multi-omics analysis and immunotherapy. These studies collectively illustrate a full-spectrum innovation pipeline from mechanistic discovery to translational clinical application. Hematology Frontier summarizes the key findings below and presents Professor Wei’s commentary on their broader significance.

From December 6–9, 2025, the 67th American Society of Hematology (ASH) Annual Meeting convened in Orlando, attracting tens of thousands of hematology experts worldwide. As the most influential international conference in the field, ASH showcases cutting-edge advances and breakthrough clinical findings each year. At this year’s meeting, an innovative study led by Dr. Wei Zhang of Lu Daopei Hospital was selected for poster presentation. The study introduced a novel loop-structured CD19/CD22 dual-target CAR-T therapy designed to overcome antigen escape and relapse—two major obstacles in B-cell malignancies. This approach offers renewed therapeutic hope for patients with refractory or relapsed B-cell non-Hodgkin lymphoma (B-NHL). We invited Dr. Zhang to elaborate on this research.

With the aging population, the demand for hematopoietic stem cell transplantation (HSCT) among elderly patients with hematologic malignancies is growing, yet clinical decision-making faces increasingly complex challenges. In the process…

In the global wave of medical innovation, emerging therapies such as CAR-T cell therapy have brought revolutionary hope for major diseases, including malignancies. However, their widespread adoption and application face significant regional imbalances, with low- and middle-income countries encountering numerous structural barriers in accessing these frontier technologies. From November 13 to 16, 2025, the 2025 International Conference on Cell and Immunotherapy (CTI 2025) was held in Hangzhou, Zhejiang. During the conference, Oncology Frontier - Hematology specially invited Professor Alejandro Madrigal from University College London (UCL) to discuss, from an international perspective and using Mexico as a case study, the core challenges Latin America faces in promoting equitable access to medical resources and introducing cutting-edge therapies. 

In today’s rapidly evolving biomedical landscape, cell therapy has emerged as a major breakthrough direction and a focal point of global scientific inquiry. Against this backdrop, during the 2025 International Cell and Immunotherapy Congress (CTI 2025), Professor Shanshan Pei of Liangzhu Laboratory and the First Affiliated Hospital of Zhejiang University School of Medicine engaged in a scholarly dialogue with Dr. João Monteiro, Editor-in-Chief of Nature Medicine.